SynthesisAbdominal radiology (New York)2025
Predicting clinically significant prostate cancer in PI-RADS 3 lesions using MRI-based radiomics: a literature review of methodological variations and performance.
Synthesis in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- mpMRI-based clinic-radiomics-deep learning model integrating lesion and PPAT for predicting csPCa in PI-RADS category 3 lesions: a multicenter study.International urology and nephrology · 2026Article
- Using Artificial Intelligence as a Risk Prediction Model in Patients with Equivocal Multiparametric Prostate MRI Findings.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the current state of MRI-based radiomics for predicting clinically significant prostate cancer (csPCa) in PI-RADS 3 lesions and assess the quality of these radiomic studies via a systematic review of the published literature.
methodsWe conducted a literature search in PubMed, EMBASE, and SCOPUS databases from January 2017 to September 2024, using search terms containing variations of PI-RADS-3 and radiomics in abstract and titles. We collected details from the radiomic workflow for each study, including statistical performance of the radiomics models (area under the curve (AUC)). We calculated the pooled AUC across the studies and a radiomics quality score (RQS) to evaluate the quality of radiomics methodology.
resultsOf 52 articles retrieved, 14 met the selection criteria. Of these, 12 studies employed 3T MRI scanners, 8 studies T2WI, DWI, ADC images for feature extraction, and 13 studies performed manual segmentation. All but two studies used the PyRadiomics platform as their feature extraction tool. The most commonly used radiomic selection methods were Least Absolute Shrinkage and Selection Operator (LASSO). The total number of features extracted ranged between 107 and 2553. The median number of radiomics features selected for use in models was 10. Nine studies (9/14) explored clinical variables in their radiomics models, with the most common being age and PSA. For building the final model, Logistic Regression, and Univariate and Multivariate modeling methods were featured across eight studies (8/14). Overall performance of the models by pooled AUC was 0.823 (95% CI, 0.72, 0.92). The mean RQS score was 15/36 (range 13-19).
conclusionMRI-based radiomic models have potential in predicting csPCa in PI-RADS-3 lesions. However, using RQS as a guide, we determined there is a clear need to improve the methodological quality of existing and future studies by focusing on extensive validation and open publishing of data for reproducibility.
Indexed as
Identifiers
40172658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.